Veeva Systems announced on August 25, 2026 that Regeneron Pharmaceuticals has committed globally to Vault CRM, the life sciences CRM Veeva has rebuilt around agentic AI. Regeneron said it plans to use the platform to generate what Veeva calls Commercial Evidence (structured insight captured from AI-assisted field engagement) to surface barriers to treatment adoption and get its medicines to eligible patients. The announcement came as a company release distributed on the wire, with a named executive on each side and a global scope; it carried no contract value, seat count, or go-live date.
“We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM, which will give our commercial teams a more connected platform and help them get faster access to the information they need for efficient decision-making,” said Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron, in the release.
Matt Farrell, president of commercial strategy at Veeva, said the company is “honored to extend our strategic partnership with Regeneron” to include Vault CRM. The word “extend” signals an existing strategic partnership, per Steinberger’s quote, now expanding to include Vault CRM on the commercial side: the side that sells Dupixent, Eylea, and Libtayo.
What Regeneron Is Actually Buying
Vault CRM is the core of Veeva’s Vault CRM Suite, the applications the company positions as the commercial execution layer for biopharma. Per Veeva’s product page, it connects sales, marketing, and medical teams on one platform with a unified customer database and embedded AI, and it counts more than 180 customers live. Its built-in agentic capabilities are four named features, all listed as available now: the Agentic Call Report, Conversational AI, Agentic Media Search, and Agentic Insight Quality.
The capability Regeneron singled out is the Agentic Call Report, the mechanism behind Commercial Evidence. In a conventional pharma CRM, a field rep’s account of a doctor visit gets compressed into structured dropdowns, because free text is where compliance risk lives. The Agentic Call Report instead lets reps capture interactions as free text or voice, runs real-time compliance checks on what they enter, and turns the result into structured data. The pitch, on Veeva’s Commercial Evidence page, is that the context a dropdown discards (which objections a prescriber actually raised, what patients are asking) becomes usable intelligence about why a treatment is or is not being adopted. Veeva’s own cited figure there: 65% of field calls identify actionable treatment barriers.
Veeva’s Commercial Evidence page says agentic AI “turns conversations and digital interactions into clean, actionable data.” That is the concrete change underneath the phrase “agentic CRM for life sciences.”
A Run of Commitments Landing Together
Regeneron’s announcement did not arrive alone. Veeva distributed a second release the same day: Biogen has also committed to Vault CRM globally, per a second Veeva release the same day. Two weeks earlier, on August 11, 2026, Veeva announced the same global commitment from Eli Lilly, with CEO Peter Gassner taking the quote slot himself.
That extends a pattern of top-tier biopharma names on the platform. Gilead Sciences and Bristol Myers Squibb have announced Vault CRM commitments (per Gilead’s CIO quote and Veeva’s BMS release), and Roche expanded its Veeva partnership. In March 2026, Veeva reported more than 125 customers live on Vault CRM across the U.S., Europe, and Japan, including multiple top-20 biopharmas. The same release moved the end-of-support date for the legacy Veeva CRM (the product built on Salesforce, which Veeva decided in 2022 to leave) up from September 2030 to the end of December 2029.
A company of Regeneron’s scale ($14.3 billion in 2025 revenue, with four blockbuster medicines and roughly 45 candidates in clinical development, per its year-end results) will take quarters to migrate a global commercial organization. The March release is where the deployment count lives, and Veeva’s product page now puts it at 180-plus, which is the metric to track as these signatures convert into live instances.
What the Paperwork Says
The August 25 release discloses no financial terms and no implementation timeline, and it attaches Veeva’s standard forward-looking-statements notice, which points to the risk factors in the company’s most recent Form 10-Q, for the fiscal quarter ended April 30, 2026. For Veeva, each announced commitment narrows the open question left by the Salesforce split: whether the industry’s largest commercial teams would follow the company onto its own platform before the 2029 support deadline forces the issue. Three global commitments in two weeks, from three of the biggest names in biopharma, is what an affirmative answer looks like on paper. The next observable checkpoint is whether the live-customer count keeps pace with the signature count.
